28 results match your criteria: "Pharmaceutical Development Center[Affiliation]"
J Lipid Res
June 2004
Pharmaceutical Development Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA.
We investigated the formation and pharmacology of prostaglandin E(3) (PGE(3)) derived from fish oil eicosapentaenoic acid (EPA) in human lung cancer A549 cells. Exposure of A549 cells to EPA resulted in the rapid formation and export of PGE(3.) The extracellular ratio of PGE(3) to PGE(2) increased from 0.
View Article and Find Full Text PDFJ Exp Ther Oncol
March 2003
Pharmaceutical Development Center, University of Texas M.D. Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA.
Pharmacokinetic studies of [3H]oleandrin, a cardiac glycoside component of Anvirzel, were conducted in mice after either an i.v. dose (40 micrograms/kg) or a p.
View Article and Find Full Text PDFCancer Chemother Pharmacol
October 2001
Pharmaceutical Development Center, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Background: Epothilone compounds (e.g. epothilones A and B) represent a new structural class of microtubule inhibitors with the remarkable ability to inhibit tumor growth of multidrug-resistant cell lines at low nanomolar or even subnanomolar concentrations.
View Article and Find Full Text PDF